Welcome back to Research Weekly.
Last week’s FDA advisory meeting produced one of the most closely watched peptide-compounding discussions in recent memory. Over two days, the committee reviewed seven peptide groups, recommended six for inclusion on the 503A Bulks List, and declined to recommend one.
This week, we’re breaking down the final results, why DSIP was treated differently, what happens next, and which peptides are already scheduled for the next FDA review.
Six Peptides Advanced. One Did Not.
Last week, the FDA’s Pharmacy Compounding Advisory Committee completed its two-day review of seven peptide-related bulk drug substances being considered for the 503A Bulks List.
The Committee Recommended Six for Inclusion:
BPC-157
KPV
TB-500
MOTS-C
Epitalon
Semax
That makes the final score:
Six Recommended. One Not Recommended.
The result was significant, but it is important to understand exactly what happened—and what did not happen.
The committee did not approve these peptides as medications. It issued recommendations about whether the bulk substances should be eligible for use in certain forms of traditional pharmacy compounding.
FDA advisory committee recommendations are nonbinding. The agency may accept, reject or modify the committee’s recommendations as it determines its next steps.
The Final Seven-Peptide Scorecard
BPC-157
FDA evaluated BPC-157 in connection with ulcerative colitis research. The committee recommended that the related bulk substances be added to the 503A Bulks List.
KPV
KPV was evaluated in connection with wound healing and inflammatory conditions. The committee recommended inclusion.
TB-500
TB-500 was evaluated in connection with wound healing. The committee recommended inclusion.
MOTS-C
MOTS-C was evaluated in connection with obesity and osteoporosis. The committee recommended inclusion.
Epitalon
Epitalon was evaluated in connection with insomnia. The committee recommended inclusion.
Semax
Semax was evaluated in connection with cerebral ischemia, migraine and trigeminal neuralgia. The committee recommended inclusion.
Not recommended for inclusion
Emideltide, also known as DSIP
Emideltide was evaluated in connection with opioid withdrawal, chronic insomnia and narcolepsy. It was the only one of the seven peptide groups that the committee did not recommend.
Why Was DSIP the Only One Rejected?
FDA staff recommended against adding all seven peptide groups reviewed during the meeting. Across the two days, the agency repeatedly raised concerns about limited evidence, incomplete safety information, chemical characterization, aggregation, immunogenicity and peptide-related impurities.
The committee disagreed with FDA staff on six of the seven substances.
Emideltide was the exception.
FDA’s review said that emideltide was not adequately characterized and could contain peptide-related impurities resulting from incomplete reactions, truncations or other issues during production.
The agency also said it lacked sufficient safety and effectiveness data for the uses being evaluated. FDA noted that approved therapies already exist for insomnia, narcolepsy and opioid withdrawal.
During the committee discussion, members who opposed inclusion pointed to the age and quality of the available evidence. Some concluded that the research was not strong enough to justify adding emideltide to the list.
Supporters offered a different position. They argued that physician and pharmacist involvement could provide greater oversight than leaving demand entirely within an inconsistent gray market. In the end, that argument was not enough to secure a majority recommendation for DSIP.
What Happens After the Committee Vote?
The process is not finished.
The Pharmacy Compounding Advisory Committee provides independent advice to the FDA, but it does not issue approvals, change federal regulations or make final agency decisions.
For the six favorably recommended substances to be formally added to the 503A Bulks List, FDA would still need to take additional regulatory action. That process may include proposed rulemaking and an opportunity for public comment.
The recommendations do not mean:
The substances are FDA-approved drugs
FDA has confirmed that they are safe or effective
A finished compounded preparation has been approved
Any specific medical claim has been accepted
The advisory vote alone immediately changes every pharmacy’s legal authority Compounded drugs do not undergo the same FDA premarket approval process as approved drug products.
The most accurate description of last week’s result is:An FDA advisory committee recommended six peptide-related bulk substances for possible inclusion on a pharmacy-compounding list. That is meaningful, but it is not the same as drug approval.
What Peptides Will FDA Review Next?
Last week’s meeting was not the end of FDA’s peptide review.
FDA has announced that the Pharmacy Compounding Advisory Committee will meet again before the end of February 2027 to consider five additional bulk drug substances
Cathelicidin, also known as LL-37
GHK-Cu
Dihexa acetate
Melanotan II
Mechano Growth Factor, Pegylated, also known as PEG-MGF
The exact meeting date, time and location have not yet been announced. FDA also has not published the final meeting agenda, briefing packages or the specific uses it will evaluate for each substance.
The agency says it plans to publish a Federal Register notice and establish a public-comment docket before the meeting.
Why the next review may be closely contested...
Several of the upcoming substances have already appeared in FDA materials discussing bulk substances that may present significant safety risks.
FDA currently states that:
It lacks sufficient safety information for LL-37 and has cited concerns from nonclinical research.
Human safety data for injectable GHK-Cu is limited.
FDA has not identified human-exposure data for Dihexa acetate.
FDA has not identified human-exposure data for PEG-MGF and has raised concerns about immunogenicity and characterization.
Published case reports involving Melanotan II have described serious adverse events.
These are FDA’s current stated concerns—not final conclusions from the future advisory meeting. The committee will review the evidence, hear presentations and public comments, and make separate recommendations when it meets.
Research Weekly will continue following the process as FDA announces the meeting date, evaluated uses, briefing documents and public-comment instructions.
This Week’s Takeaway
The July meeting showed that the advisory committee was willing to disagree with FDA staff when members believed regulated compounding could provide more oversight than the existing market.
But the rejection of emideltide also showed that the committee was not prepared to recommend every nominated substance automatically.
For now:
Six peptide groups received favorable advisory recommendations.
Emideltide was not recommended.
None became an FDA-approved drug.
Final agency action remains pending.
Five additional peptide groups are scheduled for review before the end of February 2027.
The next phase will determine whether last week’s recommendations lead to actual regulatory changes—and whether the next group receives the same level of committee support.
0 comments